In the present study, we noted that patients with advanced NSCLC carrying uncommon EGFR mutations with co-mutations of TP53 were associated with a markedly shorter time to disease progression on initial EGFR-TKIs therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.